Literature DB >> 21611979

A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study.

H Diana Rosas1, Martin Reuter, Gheorghe Doros, Stephanie Y Lee, Tyler Triggs, Keith Malarick, Bruce Fischl, David H Salat, Steven M Hersch.   

Abstract

Over the past several years, increased attention has been devoted to understanding regionally selective brain changes that occur in Huntington's disease and their relationships to phenotypic variability. Clinical progression is also heterogeneous, and although CAG repeat length influences age of onset, its role, if any, in progression has been less clear. We evaluated progression in Huntington's disease using a novel longitudinal magnetic resonance imaging analysis. Our hypothesis was that the rate of brain atrophy is influenced by the age of onset of Huntington's disease. We scanned 22 patients with Huntington's disease at approximately 1-year intervals; individuals were divided into 1 of 3 groups, determined by the relative age of onset. We found significant differences in the rates of atrophy of cortex, white matter, and subcortical structures; patients who developed symptoms earlier demonstrated the most rapid rates of atrophy compared with those who developed symptoms during middle age or more advanced age. Rates of cortical atrophy were topologically variable, with the most rapid changes occurring in sensorimotor, posterior frontal, and portions of the parietal cortex. There were no significant differences in the rates of atrophy in basal ganglia structures. Although both CAG repeat length and age influenced the rate of change in some regions, there was no significant correlation in many regions. Rates of regional brain atrophy seem to be influenced by the age of onset of Huntington's disease symptoms and are only partially explained by CAG repeat length. These findings suggest that other genetic, epigenetic, and environmental factors play important roles in neurodegeneration in Huntington's disease.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Year:  2011        PMID: 21611979      PMCID: PMC3155608          DOI: 10.1002/mds.23762

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  24 in total

1.  Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain.

Authors:  Bruce Fischl; David H Salat; Evelina Busa; Marilyn Albert; Megan Dieterich; Christian Haselgrove; Andre van der Kouwe; Ron Killiany; David Kennedy; Shuna Klaveness; Albert Montillo; Nikos Makris; Bruce Rosen; Anders M Dale
Journal:  Neuron       Date:  2002-01-31       Impact factor: 17.173

2.  Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study.

Authors:  A Feigin; K L Leenders; J R Moeller; J Missimer; G Kuenig; P Spetsieris; A Antonini; D Eidelberg
Journal:  J Nucl Med       Date:  2001-11       Impact factor: 10.057

3.  Longitudinal change in basal ganglia volume in patients with Huntington's disease.

Authors:  E H Aylward; Q Li; O C Stine; N Ranen; M Sherr; P E Barta; F W Bylsma; G D Pearlson; C A Ross
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

4.  1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers.

Authors:  B G Jenkins; H D Rosas; Y C Chen; T Makabe; R Myers; M MacDonald; B R Rosen; M F Beal; W J Koroshetz
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

5.  Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex.

Authors:  M C Polidori; P Mecocci; S E Browne; U Senin; M F Beal
Journal:  Neurosci Lett       Date:  1999-09-03       Impact factor: 3.046

6.  Trinucleotide repeat length and progression of illness in Huntington's disease.

Authors:  K Kieburtz; M MacDonald; C Shih; A Feigin; K Steinberg; K Bordwell; C Zimmerman; J Srinidhi; J Sotack; J Gusella
Journal:  J Med Genet       Date:  1994-11       Impact factor: 6.318

7.  The association of CAG repeat length with clinical progression in Huntington disease.

Authors:  A Rosenblatt; K-Y Liang; H Zhou; M H Abbott; L M Gourley; R L Margolis; J Brandt; C A Ross
Journal:  Neurology       Date:  2006-04-11       Impact factor: 9.910

8.  Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients.

Authors:  T M Horton; B H Graham; M Corral-Debrinski; J M Shoffner; A E Kaufman; M F Beal; D C Wallace
Journal:  Neurology       Date:  1995-10       Impact factor: 9.910

9.  Thinning of the cerebral cortex in aging.

Authors:  David H Salat; Randy L Buckner; Abraham Z Snyder; Douglas N Greve; Rahul S R Desikan; Evelina Busa; John C Morris; Anders M Dale; Bruce Fischl
Journal:  Cereb Cortex       Date:  2004-03-28       Impact factor: 5.357

10.  Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.

Authors: 
Journal:  Mov Disord       Date:  1996-03       Impact factor: 10.338

View more
  17 in total

Review 1.  Systems biology of neurodegenerative diseases.

Authors:  Levi B Wood; Ashley R Winslow; Samantha Dale Strasser
Journal:  Integr Biol (Camb)       Date:  2015-07       Impact factor: 2.192

2.  Within-subject template estimation for unbiased longitudinal image analysis.

Authors:  Martin Reuter; Nicholas J Schmansky; H Diana Rosas; Bruce Fischl
Journal:  Neuroimage       Date:  2012-03-10       Impact factor: 6.556

3.  Head motion during MRI acquisition reduces gray matter volume and thickness estimates.

Authors:  Martin Reuter; M Dylan Tisdall; Abid Qureshi; Randy L Buckner; André J W van der Kouwe; Bruce Fischl
Journal:  Neuroimage       Date:  2014-12-10       Impact factor: 6.556

4.  Spatiotemporal linear mixed effects modeling for the mass-univariate analysis of longitudinal neuroimage data.

Authors:  Jorge L Bernal-Rusiel; Martin Reuter; Douglas N Greve; Bruce Fischl; Mert R Sabuncu
Journal:  Neuroimage       Date:  2013-05-20       Impact factor: 6.556

5.  Consistent neurodegeneration and its association with clinical progression in Huntington's disease: a coordinate-based meta-analysis.

Authors:  Imis Dogan; Simon B Eickhoff; Jörg B Schulz; N Jon Shah; Angela R Laird; Peter T Fox; Kathrin Reetz
Journal:  Neurodegener Dis       Date:  2012-08-23       Impact factor: 2.977

6.  Cognitive and autonomic dysfunction in presymptomatic and early Huntington's disease.

Authors:  Jan Kobal; Ziva Melik; Ksenija Cankar; Martin Strucl
Journal:  J Neurol       Date:  2014-04-02       Impact factor: 4.849

Review 7.  Role of cerebral cortex in the neuropathology of Huntington's disease.

Authors:  Ana M Estrada-Sánchez; George V Rebec
Journal:  Front Neural Circuits       Date:  2013-02-18       Impact factor: 3.492

Review 8.  Asparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis).

Authors:  Julian Banerji
Journal:  Int J Mol Med       Date:  2015-07-15       Impact factor: 4.101

9.  Efficacy of selective PDE4D negative allosteric modulators in the object retrieval task in female cynomolgus monkeys (Macaca fascicularis).

Authors:  Jane S Sutcliffe; Vahri Beaumont; James M Watson; Chang Sing Chew; Maria Beconi; Daniel M Hutcheson; Celia Dominguez; Ignacio Munoz-Sanjuan
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240

10.  Preliminary analysis using multi-atlas labeling algorithms for tracing longitudinal change.

Authors:  Regina E Y Kim; Spencer Lourens; Jeffrey D Long; Jane S Paulsen; Hans J Johnson
Journal:  Front Neurosci       Date:  2015-07-14       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.